We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray (ARAY) Q4 Loss Wider than Expected, Stock Down
Read MoreHide Full Article
Shares of Accuray Inc. (ARAY - Free Report) witnessed a 13.2% plunge in after-hours trading following the company’s fourth-quarter fiscal 2016 results. The company reported a loss of 9 cents per share, wider than both the Zacks Consensus Estimate of a loss of 6 cents and the year-ago reported loss of 7 cents.
The year-over-year deterioration can be attributed to a 6.7% year-over-year decline in total revenues to $94.9 million, lower than the consensus estimate of $99 million.
Quarter Details
The downside in revenues was majorly because of declining product revenues totaling $43.8 million, 15.2% lower than the year-ago quarter. However, services revenues increased 2.2% year over year to $51.2 million.
Meanwhile, gross orders increased 12.5% year over year to $95.4 million. Net orders totaled $79.2 million, up 7.2% on a year-over-year basis. Notably, the foreign exchange adjustments (strength in Japanese Yen) positively impacted net orders by $3.5 million. Product backlog was $405.9 million, which reflects an 8.2% increase on a year-over-year basis.
Accuray reported solid growth in TomoTherapy and Multileaf Collimator (MLC) equipped CyberKnife unit volumes, with strong performance in the EIMEA region, a key area of operations for the company. The rise in gross TomoTherapy orders was buoyed by a notable seven-unit order from the National Health Service – the largest so far for Accuray.
A key development for Accuray in the reported quarter was the 510(k) FDA approval for the Radixact platform. This image-guided IMRT platform is a noteworthy positive for the company, as it foresees opportunities to boost product revenues over the long haul.
Margin Details
Total gross margin contracted 50 basis points (bps) on a year-over-year basis to 39.3%. While the product gross margins in the quarter expanded 360 bps, driven by lucrative opportunities in the EIMEA region, service gross margins declined 340 bps from the year-ago quarter to 32.9%, primarily driven by one-time employee severance expenses.
As a percentage of revenues, research and development (R&D) and selling & marketing (S&M) expenses expanded 30 bps and 120 bps, respectively. General & administrative (G&A) expenses declined 40 bps to 10.8%.
As a result, Accuray reported an operating loss of $2.9 million, wider than the prior-year quarter loss of $1.4 million.
Accuray has also initiated its financial guidance for fiscal 2017. The company projects full-year revenues in the band of $410.0 million to $420.0 million, which reflects growth of approximately 3% to 5% on a year-over-year basis, driven by continued penetration and market share gains by the TomoTherapy system. Additionally, solid momentum in CyberKnife system sales is expected to drive growth in the forthcoming quarters.
Adjusted EBITDA is anticipated in the range of $32 million to $38 million, representing year-over-year growth between 30% and 55%. Operating expenses are now expected at around $164.0 million. Backlog and gross orders are forecasted to grow around 5% in fiscal 2017.
Notably, management refrained from providing any formal guidance for the first quarter of fiscal 2017. However, it expects to rake in 45% of the total revenue in the first half of the fiscal and the remaining 55% in the second half.
Moreover, the Radixact platform is expected to prove highly accretive to earnings with new installations in the U.S. and Europe sites by the first quarter and early second quarter of fiscal 2017. Additionally, the Onrad System of Accuray has received CFDA approval for the China market earlier this month and is expected to book orders over the long haul.
Zacks Rank & Key Picks
Currently, Accuray carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include CryoLife Inc. , Masimo Corporation (MASI - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Accuray (ARAY) Q4 Loss Wider than Expected, Stock Down
Shares of Accuray Inc. (ARAY - Free Report) witnessed a 13.2% plunge in after-hours trading following the company’s fourth-quarter fiscal 2016 results. The company reported a loss of 9 cents per share, wider than both the Zacks Consensus Estimate of a loss of 6 cents and the year-ago reported loss of 7 cents.
The year-over-year deterioration can be attributed to a 6.7% year-over-year decline in total revenues to $94.9 million, lower than the consensus estimate of $99 million.
Quarter Details
The downside in revenues was majorly because of declining product revenues totaling $43.8 million, 15.2% lower than the year-ago quarter. However, services revenues increased 2.2% year over year to $51.2 million.
Meanwhile, gross orders increased 12.5% year over year to $95.4 million. Net orders totaled $79.2 million, up 7.2% on a year-over-year basis. Notably, the foreign exchange adjustments (strength in Japanese Yen) positively impacted net orders by $3.5 million. Product backlog was $405.9 million, which reflects an 8.2% increase on a year-over-year basis.
Accuray reported solid growth in TomoTherapy and Multileaf Collimator (MLC) equipped CyberKnife unit volumes, with strong performance in the EIMEA region, a key area of operations for the company. The rise in gross TomoTherapy orders was buoyed by a notable seven-unit order from the National Health Service – the largest so far for Accuray.
Accuray Inc. - Earnings Surprise | FindTheBest
A key development for Accuray in the reported quarter was the 510(k) FDA approval for the Radixact platform. This image-guided IMRT platform is a noteworthy positive for the company, as it foresees opportunities to boost product revenues over the long haul.
Margin Details
Total gross margin contracted 50 basis points (bps) on a year-over-year basis to 39.3%. While the product gross margins in the quarter expanded 360 bps, driven by lucrative opportunities in the EIMEA region, service gross margins declined 340 bps from the year-ago quarter to 32.9%, primarily driven by one-time employee severance expenses.
As a percentage of revenues, research and development (R&D) and selling & marketing (S&M) expenses expanded 30 bps and 120 bps, respectively. General & administrative (G&A) expenses declined 40 bps to 10.8%.
As a result, Accuray reported an operating loss of $2.9 million, wider than the prior-year quarter loss of $1.4 million.
ACCURAY INC Price, Consensus and EPS Surprise
ACCURAY INC Price, Consensus and EPS Surprise | ACCURAY INC Quote
Guidance
Accuray has also initiated its financial guidance for fiscal 2017. The company projects full-year revenues in the band of $410.0 million to $420.0 million, which reflects growth of approximately 3% to 5% on a year-over-year basis, driven by continued penetration and market share gains by the TomoTherapy system. Additionally, solid momentum in CyberKnife system sales is expected to drive growth in the forthcoming quarters.
Adjusted EBITDA is anticipated in the range of $32 million to $38 million, representing year-over-year growth between 30% and 55%. Operating expenses are now expected at around $164.0 million. Backlog and gross orders are forecasted to grow around 5% in fiscal 2017.
Notably, management refrained from providing any formal guidance for the first quarter of fiscal 2017. However, it expects to rake in 45% of the total revenue in the first half of the fiscal and the remaining 55% in the second half.
Moreover, the Radixact platform is expected to prove highly accretive to earnings with new installations in the U.S. and Europe sites by the first quarter and early second quarter of fiscal 2017. Additionally, the Onrad System of Accuray has received CFDA approval for the China market earlier this month and is expected to book orders over the long haul.
Zacks Rank & Key Picks
Currently, Accuray carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include CryoLife Inc. , Masimo Corporation (MASI - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>